PAPhilippe Auzeloux

Philippe Auzeloux

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe Auzeloux has a total of 234 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bimodality imaging as a companion to evaluate antitumour efficacy of TH-302 in experimental chondrosarcoma

    by Roxane Autissier, Guilhem Pagés, Erwan Boutault, Jean-Marie Bonny, Sébastien Schmitt, Philippe Auzeloux, Yannick Bidet, Flora Ponelle-Chachuat, Aurélie Dutour, Elisabeth Miot-Noirault, et al.

    The hypoxic status of cancer tumour is disparate within tumour microenvironment and is considered as the main cause of treatment resistance. Chondrosarcoma, a type of bone cancer, combines heterogonous tumour microenvironment and resistance to therapies. We aimed to image tumour microenvironment response to hypoxia activated prodrug therapy with Evofosfamide (TH-302) on a rat chondrosarcoma model thanks to an original multimodal imaging strategy. Bimodal imaging strategy consisted of nuclear imaging and MRI on TH-302 treated and control animals. To monitor TH-302 effects on tumour growth and structure, we measured T2 and ADC by MRI and we used 18F-FDG to explore tumour metabolism. 18F-FMISO and APT to Guanidyl ratio CEST MRI evaluated hypoxic status. Proteoglycans in the extracellular matrix were explored in vivo by a radiotracer targeting proteoglycans (99mTc-NTP 15 − 5) and GAG CEST MRI. Immunohistochemistry, biochemical assays and RNA sequencing were performed to confirm in vivo observations. TH-302 demonstrated a strong efficacy on tumour structure with a reduction of its volume of 75% at the end of the protocol, a modification of the tumour microstructures and a decreased of both cellularity and cell proliferation. The drug also modified the tumour metabolisms as shown by 18F-FDG PET and GLUT-1 staining for the energetic one, CEST-MRI and pimonidazole for the hypoxic status and 99mTc-NTP 15 − 5 SPECT and sGAG assay for proteoglycans. Genomic analysis shown changes in gene expression related to therapy. TH-302 shows an in vivo anti-tumour activity in chondrosarcoma. Our multimodal imaging approach allows monitoring complex exchanges between tumour cells and their neighboring under therapy.

  • Open Access

    Supplementary Figure Legends from Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept

    by Caroline Peyrode, Valérie Weber, Aurélien Voissière, Aurélie Maisonial-Besset, Aurélien Vidal, Philippe Auzeloux, Vincent Gaumet, Michèle Borel, Marie-Mélanie Dauplat, Mercedes Quintana, et al.

  • Open Access

    Supplementary Fig. S1 from Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept

    by Caroline Peyrode, Valérie Weber, Aurélien Voissière, Aurélie Maisonial-Besset, Aurélien Vidal, Philippe Auzeloux, Vincent Gaumet, Michèle Borel, Marie-Mélanie Dauplat, Mercedes Quintana, et al.

  • Open Access

    Supplementary Fig. S2 from Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept

    by Caroline Peyrode, Valérie Weber, Aurélien Voissière, Aurélie Maisonial-Besset, Aurélien Vidal, Philippe Auzeloux, Vincent Gaumet, Michèle Borel, Marie-Mélanie Dauplat, Mercedes Quintana, et al.

  • Open Access

    Supplementary Table S1 from Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept

    by Caroline Peyrode, Valérie Weber, Aurélien Voissière, Aurélie Maisonial-Besset, Aurélien Vidal, Philippe Auzeloux, Vincent Gaumet, Michèle Borel, Marie-Mélanie Dauplat, Mercedes Quintana, et al.

  • Tyrosine kinase type A–specific signalling pathways are critical for mechanical allodynia development and bone alterations in a mouse model of rheumatoid arthritis

    by Lauriane Delay, Julie Barbier, Youssef Aissouni, Alexandra Jurczak, Ludivine Boudieu, Arnaud Briat, Philippe Auzeloux, Célia Barrachina, Emeric Dubois, Denis Ardid, et al.

    Rheumatoid arthritis is frequently associated with chronic pain that still remains difficult to treat. Targeting nerve growth factor (NGF) seems very effective to reduce pain in at least osteoarthritis and chronic low back pain but leads to some potential adverse events. Our aim was to better understand the involvement of the intracellular signalling pathways activated by NGF through its specific tyrosine kinase type A (TrkA) receptor in the pathophysiology of rheumatoid arthritis using the complete Freund adjuvant model in our knock-in TrkA/C mice. Our multimodal study demonstrated that knock-in TrkA/C mice exhibited a specific decrease of mechanical allodynia, weight-bearing deficit, peptidergic (CGRP+) and sympathetic (TH+) peripheral nerve sprouting in the joints, a reduction in osteoclast activity and bone resorption markers, and a decrease of CD68-positive cells in the joint with no apparent changes in joint inflammation compared with wild-type mice after arthritis. Finally, transcriptomic analysis shows several differences in dorsal root ganglion mRNA expression of putative mechanotransducers, such as acid-sensing ionic channel 3 and TWIK-related arachidonic acid activated K+ channel, as well as intracellular pathways, such as c-Jun, in the joint or dorsal root ganglia. These results suggest that TrkA-specific intracellular signalling pathways are specifically involved in mechanical hypersensitivity and bone alterations after arthritis using TrkA/C mice.


  • Simultaneous proteoglycans and hypoxia mapping of chondrosarcoma environment by frequency selective CEST MRI

    by Roxane Autissier, Leslie Mazuel, Elise Maubert, Jean‐Marie Bonny, Philippe Auzeloux, Sébastien Schmitt, Amidou Traoré, Caroline Peyrode, Elisabeth Miot‐Noirault, Guilhem Pagés

    Purpose: To evaluate the relevance of CEST frequency selectivity in simultaneous in vivo imaging of both of chondrosarcoma’s phenotypic features, that are, its high proteoglycan concentration and its hypoxic core.Methods: Swarm rat chondrosarcomas were implanted subcutaneously in NMRI nude mice. When tumors were measurable (12‐16 days postoperative), mice were submitted to GAG, guanidyl, and APT CEST imaging. Proteoglycans and hypoxia were assessed in parallel by nuclear imaging exploiting 99mTc‐NTP 15‐5 and 18F‐FMISO, respectively. Data were completed by ex vivo analysis of proteoglycans (histology and biochemical assay) and hypoxia (immunofluorescence).Results: Quantitative analysis of GAG CEST evidenced a significantly higher signal for tumor tissues than for muscles. These results were in agreement with nuclear imaging and ex vivo data. For imaging tumoral pH in vivo, the CEST ratio of APT/guanidyl was studied. This highlighted an important heterogeneity inside the tumor. The hypoxic status was confirmed by 18F‐FMISO PET imaging and ex vivo immunofluorescence.Conclusion: CEST MRI simultaneously imaged both chondrosarcoma properties during a single experimental run and without the injection of any contrast agent. Both MR and nuclear imaging as well as ex vivo data were in agreement and showed that this chondrosarcoma animal model was rich in proteoglycans. However, even if tumors were lightly hypoxic at the stage studied, acidic areas were highlighted and mapped inside the tumor.


  • Open Access

    Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma

    by Hussein Akil, Mercedes Quintana, Jérémy H. Raymond, Tommy Billoux, Valentin Benboubker, Sophie Besse, Philippe Auzeloux, Véronique Delmas, Valérie Petit, Lionel Larue, et al.

    Purpose: To assess the efficiency of targeted radionuclide therapy (TRT), alone or in combination with MEK inhibitors (MEKi), in melanomas harboring constitutive MAPK/ERK activation responsible for tumor radioresistance. Methods: For TRT, we used a melanin radiotracer ([131I]ICF01012) currently in phase 1 clinical trial (NCT03784625). TRT alone or combined with MEKi was evaluated in three-dimensional melanoma spheroid models of human BRAFV600E SK-MEL-3, murine NRASQ61K 1007, and WT B16F10 melanomas. TRT in vivo biodistribution, dosimetry, efficiency, and molecular mechanisms were studied using the C57BL/6J-NRASQ61K 1007 syngeneic model. Results: TRT cooperated with MEKi to increase apoptosis in both BRAF- and NRAS-mutant spheroids. NRASQ61K spheroids were highly radiosensitive towards [131I]ICF01012-TRT. In mice bearing NRASQ61K 1007 melanoma, [131I]ICF01012 induced a significant extended survival (92 vs. 44 days, p < 0.0001), associated with a 93-Gy tumor deposit, and reduced lymph-node metastases. Comparative transcriptomic analyses confirmed a decrease in mitosis, proliferation, and metastasis signatures in TRT-treated vs. control tumors and suggest that TRT acts through an increase in oxidation and inflammation and P53 activation. Conclusion: Our data suggest that [131I]ICF01012-TRT and MEKi combination could be of benefit for advanced pigmented BRAF-mutant melanoma care and that [131I]ICF01012 alone could constitute a new potential NRAS-mutant melanoma treatment.


  • Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy

    by Jacques Rouanet, Valentin Benboubker, Hussein Akil, Ana Hennino, Philippe Auzeloux, Sophie Besse, Bruno Pereira, Solène Delorme, Sandrine Mansard, Michel D’incan, et al.

    In line with the ongoing phase I trial (NCT03784625) dedicated to melanoma targeted radionuclide therapy (TRT), we explore the interplay between immune system and the melanin ligand [131I]ICF01012 alone or combined with immunotherapy (immune checkpoint inhibitors, ICI) in preclinical models. Here we demonstrate that [131I]ICF01012 induces immunogenic cell death, characterized by a significant increase in cell surface-exposed annexin A1 and calreticulin. Additionally, [131I]ICF01012 increases survival in immunocompetent mice, compared to immunocompromised (29 vs. 24 days, p = 0.0374). Flow cytometry and RT-qPCR analyses highlight that [131I]ICF01012 induces adaptive and innate immune cell recruitment in the tumor microenvironment. [131I]ICF01012 combination with ICIs (anti-CTLA-4, anti-PD-1, anti-PD-L1) has shown that tolerance is a main immune escape mechanism, whereas exhaustion is not present after TRT. Furthermore, [131I]ICF01012 and ICI combination has systematically resulted in a prolonged survival (p < 0.0001) compared to TRT alone. Specifically, [131I]ICF01012 + anti-CTLA-4 combination significantly increases survival compared to anti-CTLA-4 alone (41 vs. 26 days; p = 0.0011), without toxicity. This work represents the first global characterization of TRT-induced modifications of the antitumor immune response, demonstrating that tolerance is a main immune escape mechanism and that combining TRT and ICI is promising.


  • Open Access

    Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms

    by Hussein Akil, Jacques Rouanet, Claire Viallard, Sophie Besse, Philippe Auzeloux, Jean-Michel Chezal, Elisabeth Miot-Noirault, Mercedes Quintana, Françoise Degoul